Quantcast
Last updated on April 17, 2014 at 15:26 EDT

Oramed Granted Patents in Japan and Canada for its POD(TM) Technology for the Oral Delivery of Proteins

October 3, 2013

Increases patent portfolio to 11 issued and 24 pending

JERUSALEM, October 3, 2013 /PRNewswire/ –

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer
of oral drug delivery systems, announced today that it has received two additional patent
approvals for its platform Protein Oral Delivery (POD(TM)) technology in Japan and Canada.
Both granted patents are titled “Methods and Compositions for Oral Administrations of
Proteins.”

About POD(TM) Technology

Oramed’s proprietary Protein Oral Delivery (POD(TM)) technology is based on over 30
years of research by top scientists at Jerusalem’s Hadassah Medical Center. Addressing the
obstacles to the oral administration of small protein (peptide) molecules, POD(TM)
technology both protects and enhances protein delivery and absorption via the digestive
system and into the bloodstream. In this way Oramed’s POD(TM) technology can be used to
develop oral alternatives for a number of today’s injectable therapies.

For more information on Oramed’s POD(TM) technology, please refer to the Company
website: http://www.oramed.com [
\\lonpivdocs\Avilan\AppData\Local\Microsoft\Windows\Temporary Internet
Files\Content.Outlook\U65VURWL\www.oramed.com ]

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines currently delivered via injection. Established in 2006 and based on
Oramed’s platform POD(TM) technology, Oramed is seeking to revolutionize the treatment of
diabetes through its proprietary flagship product, an orally ingestible insulin capsule
(ORMD-0801 [http://oramed.com/index.php?page=14 ]) currently initiating Phase 2 clinical
trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug
application with the U.S. Food and Drug Administration, and with its oral exenatide
capsule (ORMD-0901; a GLP-1 analog [http://oramed.com/index.php?page=14 ]), with trials on
healthy volunteers (Phase 1b) and T2DM patients (Phase 2a) underway. Oramed is also moving
forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The
company’s corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please
visit http://www.oramed.com.

Forward-looking statements: This press release contains forward-looking statements.
For example, we are using forward-looking statements when we discuss our clinical trials
or revolutionizing the treatment of diabetes with our products. These forward-looking
statements and their implications are based on the current expectations of the management
of Oramed only, and are subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the forward-looking
statements, including the risks and uncertainties related to the progress, timing, cost,
and results of clinical trials and product development programs; difficulties or delays in
obtaining regulatory approval or patent protection for our product candidates; competition
from other pharmaceutical or biotechnology companies; and our ability to obtain additional
funding required to conduct our research, development and commercialization activities. In
addition, the following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: changes in technology
and market requirements; delays or obstacles in launching our clinical trials; changes in
legislation; inability to timely develop and introduce new technologies, products and
applications; lack of validation of our technology as we progress further and lack of
acceptance of our methods by the scientific community; inability to retain or attract key
employees whose knowledge is essential to the development of our products; unforeseen
scientific difficulties that may develop with our process; greater cost of final product
than anticipated; loss of market share and pressure on pricing resulting from competition;
laboratory results that do not translate to equally good results in real settings; our
patents may not be sufficient; and final that products may harm recipients, all of which
could cause the actual results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as otherwise required by law,
Oramed undertakes no obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed’s reports filed from time to
time with the Securities and Exchange Commission.

        Company Contact:
        Oramed Pharmaceuticals
        Aviva Sherman
        Office: +972-2-566-0001
        Mobile: +972-54-792-4438
        Email: aviva@oramed.com

SOURCE Oramed Pharmaceuticals Inc.


Source: PR Newswire